Patient Safety Notice
PSN039 / January 2018

Safe Transfusion Practice - Use a bedside checklist

To: All NHS Wales Chief Executives, Medical Directors, Directors of Nursing and Patient Safety Teams.

Since the first report in 1997 the UK national haemovigilance surveillance programme, Serious Hazards of Transfusion (SHOT), has repeatedly identified that patients are harmed, and some die, as a result of being given the incorrect type of blood.

In 2014 a patient died as a result of an ABO-incompatible transfusion (wrong blood type administered) in a high profile case. The nurse collected, and then administered a unit intended for another patient with a similar name. This would have been prevented if the final bedside check had been undertaken correctly.

There were seven ABO-incompatible transfusions reported to SHOT in 2015, and three in 2016. All of these were preventable. In addition to the risk of ABO-incompatible transfusion, patients may have other specific, and sometimes critical, transfusion requirements such as irradiated blood, CMV negative serology blood and extended phenotype blood.

Two critical points occur in preparation for transfusion; the first is to correctly identify the patient and label the sample when taking blood for a pre-transfusion blood sample, and the second is to check the details on the unit of blood and the patient’s identity at the point of transfusion.

Evidence from SHOT shows that the bedside check performed at the point of transfusion is not always undertaken correctly and that this puts patients at risk of serious complications or death. SHOT therefore recommends a structured process with a bedside checklist which must confirm the following:

- Positive patient identification including first name, family name and date of birth; unless impossible, this should be done by asking the patient to state their names and date of birth.

Actions

When: As soon as possible but no later than 15 February 2018

Who: All organisations providing NHS funded care which involves the provision of blood transfusions.

1. Organisations should assess their bedside systems (including electronic systems) to ensure a confirmatory step is in place where the individual performing the checks must sign to say all steps have been followed.

2. This notice (and supporting Information) should be circulated to all relevant staff, including community nursing staff and midwives who may be involved in the transfusion of blood products in the community.

Share any learning from local investigations or locally developed good practice resources by emailing: ImprovingPatientSafety@gov.wales

www.patientsafety.wales.nhs.uk

Queries should be sent to: ImprovingPatientSafety@Gov.Wales
- unique identification number (hospital number, NHS number)
- check that it is the correct and compatible component (against the prescription and label on the component) for this patient at this time
- check that the component meets any specific requirements for that patient

The Welsh Health Circular (2007) 042 (2) requires the use of the first line of address as a core identifier for patients undergoing blood transfusion procedures in Wales following previous adverse events associated with patients of the same name and date of birth in Wales.

This notice requires organisations to review current blood transfusion processes for compliance with a bedside check list. The All Wales Transfusion Record endorsed by NHS Wales and already in use in most organisations incorporates a pre-transfusion patient checklist as part of the transfusion administration documentation. Correct use of this record meets the recommendations made by SHOT for a pre transfusion bedside check list and provides an appropriate solution to this notice. Please see the appendix below for additional information.

Appendix

Wrong transfusions: Background

SHOT is the UK national haemovigilance scheme and has reported since 1996 on adverse incidents related to blood transfusion (20 years). Every year the largest group of reports are those where an incorrect blood component was transfused. This includes incidents where the wrong component was transfused, for example red cells were given when platelets had been prescribed. It includes transfusions where the component transfused was intended for a different patient. In the first year of reporting 22% National Health Service organisations participated but in recent years this has increased to 100%. These data show that despite the introduction of competency assessments (3) for all staff members who participate in the transfusion process, the numbers of wrong transfusions are not reducing. Over the same period of time the number of serious reactions allergic/febrile, which cannot be predicted have increased in line with the total number of reports.

Categories of incorrect blood components transfused (IBCT)

ABO-incompatible red cell transfusions are the most serious preventable errors and are reportable as ‘never events’ (4). While these may cause death or serious harm, in about two thirds there are no or minor adverse effects. These events may therefore be under-reported. Altogether 302 have been reported to SHOT. Twenty patients have died and an additional 80 suffered serious harm. ABO-incompatible transfusions have decreased from a maximum of 34 reported in 1999/2000 to between 3 and 14 between 2007 and 2016 (1). These potentially fatal incidents result from two main causes, the wrong patient is sampled (‘wrong blood in tube’ WBIT) or the component is transfused to the wrong patient.

The risk of sampling the wrong patient is reduced by ensuring every patient has two independent samples taken prior to a first transfusion. This group-check sample is recommended in British Society for Haematology guidelines (5).

www.patientsafety.wales.nhs.uk

Queries should be sent to: ImprovingPatientSafety@Gov.Wales
This policy is now in place in most hospitals (129/177, 73% of respondents to the recent survey from the National External Quality Assessment scheme for blood transfusion). Taking a single sample, splitting it into two and sending them separately at different times completely defeats the purpose of this safety step. In 2016 two of the three ABO-incompatible transfusions were caused by WBIT. If a sample is taken from the wrong patient and there is no group check, a wrong transfusion cannot then be detected by the bedside check. It is notable that in 2016 there were 3 ABO-incompatible transfusions but a further 264 near miss events due mainly to WBIT. These were detected because there was a different historical group. These incidents were caused by poor practice associated with failure to correctly identify the patient and labelling the blood sample tubes away from the bedside.

Other wrong transfusions include giving D-positive cellular components to a D-negative recipient. This carries about a 25% risk of development of anti-D antibodies which can cross the placenta in D-negative women causing damage to fetal red cells if the baby is D-positive.

**Wrong components transfused.** The patient is transfused a different component than the one prescribed or authorised, for example is given platelets instead of red cells.

**Specific requirements not met.** Some patients require components selected for additional features such as irradiated cellular components for certain indications where patients have weakened immune systems (6). This is to reduce the risk of transfusion-associated graft versus host disease where transfused lymphocytes engraft in the recipient. The outcome is usually fatal. Some protection is offered by pre-storage universal Leucodepletion. Cumulative SHOT data show that more than 1300 patients have received non-irradiated components since the introduction of Leucodepletion in 1999, one patient receiving more than 450 non-irradiated components. Additional specific requirements include cytomegalovirus-screened cellular components for pregnant women (unless emergency transfusion is needed), and red cells matched for additional blood group antigens are recommended for patients with haemoglobin disorders such as the sickle cell diseases and Thalassaemia to reduce the risk of potentially serious haemolytic reaction. This is particularly important for patients with known irregular red cell antibodies who require units negative for those antigens.

These specific requirements must be notified to the transfusion laboratory and should be included in the request; they should be noted on the prescription and checked prior to administration. These must be included in the bedside checklist.

**References**


